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A B S T R A C T
Total tanshinones are lipophilic active constituents extracted from Salvia miltiorrhiza Bge.
Tanshinone IIA and cryptotanshinone are the major components in total tanshinones.
However, the bioavailability of both compounds is low due to poor water solubility.To enhance
the solubility and dissolution rate of tanshinone IIA, cryptotanshinone and total tanshinones,
three common used hydrophilic carriers including PEG 6000, poloxamer 188 and PVP K30
were used to prepare the solid dispersions at different ratios, respectively. The solid dis-
persions were characterised by scanning electron microscopy (SEM), differential scanning
calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR). The results of powder
X-ray diffraction confirmed the microcrystal state of total tanshinones in solid dispersions
and no chemical interaction between total tanshinones and carriers was observed in FTIR
spectra. The solubility and dissolution rate of tanshinone IIA and cryptotanshinone were
significantly increased in all solid dispersions. Regarding tanshinone IIA, the solubility and
dissolution rate of in solid dispersions prepared with poloxamer 188 were significantly higher
than that with PEG 6000 and PVP K30. The higher solubility and dissolution rate of
cryptotanshinone were obtained in solid dispersion of PVP K30 than that of PEG 6000 solid
dispersions but no significant difference from poloxamer 188 solid dispersions. The results
indicate that the superior carrier for preparation of tanshinone IIA and total tanshinones
solid dispersions is poloxamer 188, and that for cryptotanshinone is PVP K30.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Tanshinones, the lipophilic active constituents of Salvia
miltiorrhiza Bge., have been extensively used as traditional
Chinese medicine (TCM) for treating cardiovascular condi-
tions [1], including coronary disease, angina pectoris, cerebral
haemorrhage, diabetes mellitus, as well as some infectious dis-
eases [2]. Tanshinones have also been shown to be effective
in reducing brain injury induced by middle cerebral artery oc-
clusion in animals [3,4]. More recently, some studies have
reported that tanshinones are also active against a variety of
human cancer cell lines [5–12], indicating its benefits to the
cancer therapy.
Dosage forms of tanshinones are primarily tablets and cap-
sules, which have been prepared and are commercially available
in China. Total tanshinones mainly consist of tanshinone IIA,
IIB, cryptotanshinone (CT) and tanshinone I [13]. The chemi-
cal structures of tanshinone IIA and cryptotanshinone were
shown in Fig. 1. Natural tanshinones have proved to have poor
bioavailability due to their poor water solubility, insufficient
dissolution rates [14] and first pass metabolism [15]. For
example, the p.o. and i.p. bioavailabilities of CT in rats were es-
timated as 2.1% and 10.6% respectively when CT was dosed
at 100 mg/kg of body weight [16]. The oral bioavailability of
tanshinone IIA was also extremely low with an absolute
bioavailability below 3.5% [17]. The maximum plasma concen-
tration of CT and tanshinone IIA was below 20 ng/ml [18].Thus,
improving the solubility and dissolution rate of tanshinones
are important in the formulation design of tanshinone. For this,
a water soluble tanshinone IIA derivative, sodium tanshinone
IIA sulphonate (sodium tanshinone IIA sulphonate injec-
tion), has been used clinically for treating cardiovascular
diseases for more than 30 years in China [19]. However, the in-
trinsic anti-tumour activities of tanshinone IIA might be
eliminated due to the structure modification, while the cura-
tive effects on cardiovascular disorders still remain [9].
Therefore, it is very meaningful to explore a technology without
chemical structural modifications to enhance the bioavailability
of tanshinones.
Currently, numerous pharmaceutical strategies have been
employed to overcome the poor dissolution rate of tanshinones
such as solid lipid nanoparticles [20], tanshinone IIA inclu-
sion compound with HP-β-CD [21], pulsatile release pellet [22],
intravenous lipid emulsion [9] andmicroemulsion [23]. It is note-
worthy that solid dispersion (SD) has demonstrated as a highly
effective strategy to improve the dissolution rate and the
bioavailability of poorly soluble drugs [24]. Solid dispersion con-
sists of at least two different components, generally a
hydrophilic matrix and a hydrophobic drug.The enhanced dis-
solution rate of drugs from solid dispersions may be relative
to four different mechanisms, that is reduced particle size (mo-
lecular or microcrystalline dispersions), improved wettability,
increased porosity or present in amorphous state by dispers-
ing drugs into inert hydrophilic carriers in the solid state [25,26].
However, solid dispersion of tanshinones has not been fully
elucidated so far.
Various hydrophilic carriers, such as polyethylene glycols
(PEG), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellu-
lose (HPMC), poloxamers, gums, sugar,mannitol, and urea, have
been used in solid dispersion for improving dissolution char-
acteristics and bioavailability of poorly aqueous-soluble drugs
[27]. Among them, PEG, poloxamers and PVP are the com-
monly used hydrophilic carriers. PVP based SD is usually
prepared by solvent evaporation method because of its higher
melting point (130 °C).While poloxamer 188 and PEG 6000 based
SD can be prepared by a melting method due to their lower
melting point (52–57 °C, 65 °C) [28].
Recently tanshinone IIA-poloxamer 188 solid dispersion has
been reported, and improved solubility and dissolution rate of
tanshinone IIA were achieved [28]. However, it is not clear as
to what extent of different hydrophilic carriers affects the solu-
bility and dissolution characteristics of tanshinone IIA, especially
total tanshinones. Therefore, this study was designed to in-
vestigate the effects of PEG 6000, poloxamer 188 and PVP K30
on the solubility and dissolution rate of key constituents of
tanshinone IIA and CT in total tanshinones in various SDs and
their physicochemical properties. Pure tanshinone IIA and CT
were also studied and compared with the total tanshinones
in the same conditions.
2. Material and methods
2.1. Materials
The following materials were commercially purchased:
Tanshinone IIA and cryptotanshinone reference standard (Na-
tional Institute for Food and Drug Control, China, purity ≥ 99%).
Poloxamer 188 (Pharmaceutical Factory of Shenyang Pharma-
ceutical University, China), Polyethylene glycol 6000 (PEG 6000)
(Tanjin Binhai Chemical Factory, China), Polyvinylpyrrolidone
K30 (PVP K30) (Shanghai Lanji Technology Development Co.,
Ltd, China). Bulk powders of total tanshinones (purity > 90%,
the content of tanshinone IIA and cryptotanshinone were
298.79 mg/g and 196.47 mg/g, respectively by HPLC), pure
tanshinone IIA (purity ≥ 98%) and pure cryptotanshinone
(purity ≥ 98%) were purchased from Xi’an Haoxuan Biological
Technology Co., Ltd.All solvents were of chromatographic grade
Fig. 1 – HPLC chromatogram of total tanshinones.
Conditions: Column: Welchrom C18 (150 mm × 4.6 mm,
5 μm); mobile phase: methanol and water (80:20 v/v);
column temperature: 30 °C; flow rate: 1.0 ml/min, detection
wavelength: 270 nm.
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or analytical grade. Deionised water was purified by a Milli-Q
water purification system.
2.2. Preparation of solid dispersions and physical
mixtures
2.2.1. Physical mixtures
Physical mixtures of tanshinone IIA, CT and total tanshinones
were prepared by mixing the compounds with poloxamer 188,
PEG 6000 and PVP K30 at ratio of 1:6 (w/w), respectively. After
thoroughlymixing, the powders were passed through a 60mesh
sieve for further experiments.
2.2.2. Solid dispersions
SDs of tanshinone IIA, CT and total tanshinones were pre-
pared with poloxamer 188, PEG 6000 and PVP K30 respectively,
at three different ratios (1:4, 1:6, 1:8 w/w). Briefly, poloxamer
188 or PEG 6000 was put into an evaporating dish and stirred
on a water bath (70 °C), then tanshinone IIA, CT and total
tanshinones powder were added respectively and mixed well.
The evaporating dishes were put into a −20 °C fridge for 1 h.
The solidified mass was then ground with a mortar and pestle
into powder and passed through a 60 mesh sieve. For PVP K30
SDs, PVP K30 was first mixed with tanshinone IIA, CT or total
tanshinones separately, and then dissolved with absolute
ethanol. The ethanol was evaporated on a 60 °C water bath.
The solidified mass was placed in a 40 °C drying oven for 24 h,
then ground into powder and passed through a 60 mesh sieve.
The obtained SDs were stored in a desiccator for further
experiments.
2.3. HPLC analysis of tanshinone IIA and
cryptotanshinone
The concentration of tanshinone IIA and cryptotanshinone in
the testing medium was determined using a Shimadzu LC-
2010AHT liquid chromatographic system (Shimadzu Corp,
Japan) under the following conditions: Welchrom C18
(150 mm × 4.6 mm, 5 μm) column and a Phenomenex C18 guard
column, methanol and water (80:20 v/v) as mobile phase at a
flow rate of 1.0 ml/min, UV detection at 270 nm.
2.3.1. Linearity determination
Accurately weighed reference compounds tanshinone IIA and
CT were dissolved in methanol to produce 50 μg/ml solutions
respectively, as standard solutions, and were stored in a fridge
(4 °C) for further use.The standard solutions were diluted with
methanol to produce solutions containing tanshinone IIA and
CT 1 μg/ml, 2 μg/ml, 5 μg/ml, 10 μg/ml, 20 μg/ml, 30 μg/ml, 40 μg/
ml and 50 μg/ml, respectively. 10 μl of the above solutions were
injected into column for HPLC analysis. The regression equa-
tions were calculated in the form of Y = aX + b, where Y is peak
area and X is compound amount determined.
2.3.2. Precision and repeatability
The precision and repeatability were determined by analysing
the same mixed standard solution in methanol for 6 times
within one day (0, 2, 4, 6, 10, 24 h).The RSD% of peak areas was
taken as the measures of precision and repeatability.
2.3.3. Recovery
Recovery test was conducted to evaluate accuracy of the HPLC
method. Approximate amounts of total tanshinones solid dis-
persions (with poloxamer 188, PEG 6000 and PVP K30 at the
ratio of 1:6 w/w, equivalent to total tanshinones 3 mg) were
dissolved with methanol in a 10 ml volumetric flask by
ultrasonication for 10 min. The samples were then replen-
ished with methanol to the volume. 1 ml of the solution was
spiked with 1 ml of the standard reference solution and mixed
well. The mixtures were injected (5 μl) into column for HPLC
analysis. The average recoveries were determined by the fol-
lowing formula: recovery (%) = (amount found − original
amount)/amount spiked × 100%, and RSD (%) = (SD/mean) ×
100%.
2.4. Determination of solubility
The solubility of SDs, physical mixtures and raw material of
tanshinone IIA, CT and total tanshinones were determined by
adding appropriate amounts of each compound(s) to test tubes
containing 5 ml of degassed water. The sealed test tubes were
shaken at 25 °C for 24 h, and then centrifuged at 3750 rpm for
15 min. The supernatant was filtered with 0.25 μm millipore
filter and the amount of relevant compound(s) in the filtrate
was determined by HPLC.
2.5. Determination of dissolution rate
Dissolution rate of samples of SD and physical mixture was
performed by an intellective dissolution apparatus (D-800LS,
Tianda Tianfa Technology Co. Ltd, Tianjin, China). Samples
(equivalent to pure tanshinone IIA and CT 5 mg, tanshinone
IIA 7.5 mg and CT 5 mg in total tanshinones) were sus-
pended in 900 ml of degassed deionised water at 37 ± 0.5 °C.
Paddle method was employed at a rotation speed of 100 rpm
according to Chinese Pharmacopoeia 2010 edition. 2 ml of the
samples were withdrawn at 5, 10, 20, 30, 40, 50, 60, 90, and
120 min and equal volumes of degassed deionised water were
replenished into the dissolution cup after each sample was
taken. The sample solutions were filtered through a 0.45 μm
millipore filter, the initial sample volume (0.5 ml) was dis-
carded and final 1.5 ml was collected and analysed by HPLC.
2.6. Characterisation of solid dispersions
2.6.1. Scanning electron microscopy
The surface morphology of tanshinone IIA, CT, total
tanshinones, three hydrophilic carriers, SDs and the relevant
physical mixtures were examined by scanning electron mi-
croscope (S-4800, Hitachi, Japan) at 1.0 kV. The samples were
fixed on double-sided adhesive tape and made electrically con-
ductive by sputter-coating with gold using Hitachi Ion Sputter
(E-1045, Hitachi, Japan) in a vacuum (6 Pa) for 1 minute at 15mA.
Scanning electronmicroscopy (SEM) images were taken to show
the appearance of the entire sample.
2.6.2. Differential scanning calorimetry
The differential scanning calorimetry (DSC) thermal traces were
examined by a differential scanning calorimeter (PYRIS
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Diamond DSC, Perkin-Elmer Company, USA).The samples were
encapsulated in aluminium crucible and heated at a rate of
20 °C/min from 45 °C to 260 °C. The empty aluminium cru-
cible was used as reference. The flow rate of nitrogen gas was
set at 20 ml/min during the whole study.
2.6.3. Fourier transform infrared spectroscopy analysis
Fourier transform infrared spectroscopy (FTIR) spectra were ob-
tained by FTIR spectrometer (BRUKERTENSOR27, Germany).The
samples were mixed thoroughly with potassium bromide at
1:100 (sample: potassium bromide) weight ratio. After being
ground, the powders were pressed at 10 MPa for 1 min in a hy-
draulic press to prepare potassium bromide discs. Scans were
obtained at a resolution of 4/cm from 4000 to 400/cm. All the
studies were performed in triplicate.
2.6.4. Powder X-ray diffraction
Powder X-ray diffraction (PXRD) was performed on a D/max
3C X-ray diffractometer (Rigaku, Japan). Data were collected
using Ni filtered, CuKα radiation at a voltage of 35 kV and a
35 mA current. The scanning rate was 1°/min over the 5 to 55°
diffraction angle (2θ) range.
3. Results and discussion
3.1. HPLC analysis of tanshinone IIA and
cryptotanshinone
The HPLC method used in this study showed an excellent
linearity with the regression equations of tanshinone IIA
and CT, which were y = 9859.8x − 61239 (r2 = 0.9997) and,
y = 6761.1x − 38829 (r2 = 0.9997) respectively, within the range
of 20–750 ng. The precision and repeatability of the assay are
satisfactory with RSD% of tanshinone IIA 0.36% and CT 0.58%.
The results of recovery test in three hydrophilic carriers were
showed in Table 1.
3.2. The solubility of tanshinone IIA and
cryptotanshinone in different solid dispersions, physical
mixtures and raw materials
The solubility of tanshinone IIA and CT in different SDs,
physical mixtures (mix 1:6), and raw materials in degassed
water was shown in Table 2. In all prepared solid disper-
sions, the solubilities of tanshinone IIA and CT were increased
with higher ratios (w/w) of hydrophilic carriers (1:8 > 1:6 > 1:4).
The solubility of physical mixtures was much less than that
of solid dispersions, but still greater than relevant raw
materials. Among three carriers, Poloxamer 188 was most
effective in enhancing the solubility of tanshinone IIA in
both tanshinone IIA and total tanshinones SDs. The solubil-
ity of tanshinone IIA in Poloxamer 188 SDs was maximum
enhanced 544-fold compared to the pure drug. However, CT
was most effectively enhanced by both Poloxamer 188 and
PVP K30. The solubility of CT in Poloxamer 188 and PVP K30
SDs was enhanced to maximum 108-fold and 107-fold com-
pared to the pure drug respectively. The results also indicated
that the solubility of tanshinone IIA and CT from total
tanshinone SDs was higher than that from pure compound
SDs.
Table 1 – Recovery of tanshinone IIA and cryptotanshinone in three hydrophilic carriers.
Analyte PEG 6000 Poloxamer 188 PVP K30
Recovery (%) RSD% Recovery (%) RSD% Recovery (%) RSD%
Tanshinone IIA 96.23 1.86 102.61 1.73 97.27 1.31
Cryptotanshinone 101.83 1.06 96.88 1.97 103.87 0.98
Table 2 – The solubility of tanshinone IIA and cryptotanshinone in solid dispersions, physical mixtures and raw
materials (n = 3).
Sample Solubility (μg/ml)
Hydrophilic
carrier
Ratio
(w/w)
Tanshinone
IIA
Cryptotanshinone Total tanshinones
Tanshinone IIA Cryptotanshinone
PEG 6000 SD1:8 5.75 ± 0.020 6.52 ± 0.059 29.64 ± 0.098 13.15 ± 0.031
SD1:6 1.13 ± 0.057 4.39 ± 0.033 9.96 ± 0.087 5.69 ± 0.057
SD1:4 0.40 ± 0.006 1.64 ± 0.012 3.46 ± 0.049 3.01 ± 0.031
Mix 1:6 0.21 ± 0.005 1.10 ± 0.035 1.54 ± 0.013 0.83 ± 0.001
Poloxamer 188 SD1:8 81.59 ± 0.022 18.97 ± 0.109 101.96 ± 0.083 37.03 ± 0.082
SD1:6 49.00 ± 0.054 15.28 ± 0.045 54.74 ± 0.094 29.05 ± 0.088
SD1:4 18.95 ± 0.082 9.34 ± 0.053 28.51 ± 0.068 13.10 ± 0.063
Mix 1:6 1.58 ± 0.042 3.88 ± 0.075 25.10 ± 0.040 5.73 ± 0.057
PVP K30 SD1:8 1.82 ± 0.039 17.60 ± 0.080 20.33 ± 0.078 37.40 ± 0.082
SD1:6 0.60 ± 0.002 10.51 ± 0.074 16.19 ± 0.095 32.44 ± 0.049
SD1:4 0.34 ± 0.005 8.91 ± 0.033 14.14 ± 0.038 30.74 ± 0.094
Mix 1:6 0.26 ± 0.002 4.95 ± 0.015 6.52 ± 0.040 5.20 ± 0.019
Raw material 0.15 ± 0.002 0.26 ± 0.012 0.87 ± 0.009 0.35 ± 0.004
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Fig. 2 – Dissolution profiles of tanshinone IIA and cryptotanshinone from solid dispersions (1:4, 1:6, 1:8 w/w) and physical
mixtures (mix 1:6 w/w) of tanshinone IIA and cryptotanshinone. (A) Tanshinone IIA-PEG 6000 solid dispersions and
mixture, (B) tanshinone IIA-poloxamer 188 solid dispersions and mixture, (C) tanshinone IIA-PVP K30 solid dispersions
and mixture, (D) cryptotanshinone-PEG 6000 solid dispersions and mixture, (E) cryptotanshinone-poloxamer 188 solid
dispersions and mixture, (F) cryptotanshinone-PVP K30 solid dispersions and mixture, (G) tanshinone IIA from total
tanshinones-PEG 6000 solid dispersions and mixture, (H) tanshinone IIA from total tanshinones-poloxamer 188 solid
dispersions and mixture, (I) tanshinone IIA from total tanshinones-PVP K30 solid dispersions and mixture, (J)
cryptotanshinone from total tanshinones-PEG 6000 solid dispersions and mixture, (K) cryptotanshinone from total
tanshinones-poloxamer 188 solid dispersions and mixture, (L) cryptotanshinone from total tanshinones-PVP K30 solid
dispersions and mixture.
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3.3. The dissolution rate of tanshinone IIA and
cryptotanshinone in different solid dispersions and physical
mixtures
The dissolution curves of different SDs and relevant physical
mixtures were shown in Fig. 2. Cumulative release of tanshinone
IIA and CT from SDs and physical mixtures during 120 min
dissolution tests were shown in Fig. 3.The dissolution rate was
plotted as the percentage of accumulative dissolution of solutes
in dissolution medium from the SDs and physical mixtures.
The dissolution rates of tanshinone IIA and CT were signifi-
cantly increased with the higher ratio of hydrophilic carries
in all three carriers SDs. The order of ratio is 1:8 > 1:6 > 1:4 (w/
w). The dissolution rate in SDs was also significantly greater
Fig. 3 – Cumulative release of tanshinone IIA and cryptotanshinone from solid dispersions and physic mixtures during
120 min dissolution test. (A) Tanshinone IIA and cryptotanshinone solid dispersions, (B) total tanshinones solid
dispersions.
Fig. 4 – Scanning electron microphotographs of raw materials (magnification 1k–5k). (A) PEG 6000, (B) poloxamer 188, (C)
PVP K30, (D) tanshinone IIA, (E) cryptotanshinone, (F) total tanshinones.
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than that of the corresponding physical mixtures. Similar results
for tanshinone IIA-poloxamer SD have been obtained in another
study [28].
The dissolution rate of tanshinone IIA from the tanshinone
IIA-poloxamer 188 solid dispersions and total tanshinones-
poloxamer 188 SDs was faster than that of PEG 6000 and PVP
K30 SDs. On the other hand, the dissolution rate of CT from
CT-PVP K30 and total tanshinones-PVP K30 SDs was great and
faster than that of PEG 6000 SDs, but no significant differ-
ence was found with relevant poloxamer 188 solid dispersions.
Combining the results of cumulative release of tanshinone IIA
and CT from SDs and physical mixtures during 120 min dis-
solution test periods (Fig. 3) and solubility of solid dispersions,
poloxamer 188 exhibited a significantly higher release of
tanshinone IIA from tanshinone IIA and total tanshinones SDs,
while PVP K30 exhibited a significantly higher release of CT
from CT and total tanshinones SDs.Thus, poloxamer 188 seems
to be the best carrier for preparation of tanshinone IIA and total
tanshinones SDs, and PVP K30 seems to be the best carrier for
CT SD. In overall consideration, poloxamer 188 would be the
best carrier for total tanshinones SD.
Poloxamer 188 is a kind of nonionic surfactant. The signifi-
cantly increased solubility and dissolution rate of tanshinone
IIA and CT in Poloxamer 188 SDs may be relative to its
wettability, emulsification and solubilisation effects.
3.4. Scanning electron microscopy
The scanning electron microscopy (SEM) images of raw ma-
terials of tanshinone IIA, CT, total tanshinones, PEG 6000,
poloxamer 188 and PVP K30 were shown in Fig. 4. The crystal
morphology of pure tanshinone IIA was an acicular crystal, CT
was a columnar crystal and total tanshinones was a crumb
composed of small columnar crystals. PEG 6000 and poloxamer
188 powder had an irregular shape. PVP K30 was a ball with a
smooth surface.
The scanning electron microphotographs of physical mix-
tures and SDs were shown in Figs. 5–7. Morphology of the
physical mixtures clearly indicated that the crystals of
tanshinone IIA, CT and total tanshinones were mixed with PEG
6000, poloxamer 188, PVP K30 particles or adhered to their
surface (Fig. 5B, D, F; Fig. 6B, D, F and Fig. 7B, D, F). The results
Fig. 5 – Scanning electron microphotographs of solid dispersions and physical mixtures with PEG 6000 as carrier (1:6 w/w).
(A) Tanshinone IIA-PEG 6000 solid dispersion, (B) tanshinone IIA-PEG 6000 physical mixture, (C) cryptotanshinone-PEG 6000
solid dispersion, (D) cryptotanshinone-PEG 6000 physical mixture, (E) total tanshinones-PEG 6000 solid dispersion, (F) total
tanshinones-PEG 6000 physical mixture.
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confirmed the presence of crystalline tanshinone IIA, CT and
total tanshinones in physical mixtures. In contrast, the crys-
tals of tanshinone IIA, CT and total tanshinones were invisible
in SDs under the same condition.The SDs appeared in the form
of irregular particles (Fig. 5A, C, E; Fig. 6A, C, E and Fig. 7A, C,
E). The results demonstrated that tanshinone IIA, CT and total
tanshinones possibly dispersed in solid dispersions in mo-
lecular, amorphous or microcrystal form.
3.5. Differential scanning calorimetry
Fig. 8 represents the DSC thermograms of PEG 6000, poloxamer
188, PVP K30, tanshinone IIA, CT, total tanshinones and their
SDs and physical mixtures (1:6 w/w). The thermograms re-
vealed the single endothermic peaks of tanshinone IIA, PEG
6000 and poloxamer 188 at 220.16 °C, 65.12 °C and 57.24 °C, re-
spectively. The heating scans for solid dispersions of PEG 600-
tanshinone IIA and poloxamer 188-tanshinone IIA showed
melting peak at 62.03 °C and 55.40 °C with no endothermic peak
corresponding to tanshinone IIA. Similarly, physical mixtures
of PEG 6000-tanshinone IIA and poloxamer 188-tanshinone IIA
showed melting peak at 65.10 °C and 57.18 °C with no endo-
thermic peak corresponding to tanshinone IIA.
It is noticed that the endothermic peaks in solid disper-
sions of PEG 6000-tanshinone IIA and poloxamer 188-
tanshinone IIA were altered from 65.12 °C and 57.24 °C to
62.03 °C and 55.40 °C, respectively.These may be due to the for-
mation of eutectic mixtures in SDs leading to the depression
of melting point. However, in physical mixtures of PEG 6000-
tanshinone IIA and poloxamer 188-tanshinone IIA, the
endothermic peaks of carriers remained the same as pure PEG-
6000 and poloxamer 188.These unchanged endothermic peaks
for carriers and disappeared peaks of tanshinone IIA in physi-
cal mixtures revealed that the drug substance was slowly
dissolved in molten PEG 6000 and poloxamer 188 during the
rising of temperature.
Fig. 6 – Scanning electron microphotographs of solid dispersions and physical mixtures with poloxamer 188 as carrier (1:6
w/w). (A) Tanshinone IIA-poloxamer 188 solid dispersion, (B) tanshinone IIA-poloxamer 188 physical mixture, (C)
cryptotanshinone-poloxamer 188 solid dispersion, (D) cryptotanshinone-poloxamer 188 physical mixture, (E) total
tanshinones-poloxamer 188 solid dispersion, (F) total tanshinones-poloxamer 188 physical mixture.
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As an amorphous polymer, PVP K30 did not show any fusion
peak or phase transition, apart from a broad endothermic peak,
as a result of dehydration, which lies between 80 °C and 120 °C
[29]. In addition, it is difficult to discern the endothermic peak
of tanshinone IIA in physical mixture and SDs of the PVP K30.
Similar results were observed in CT, total tanshinones SDs
and the corresponding physical mixtures using PVP K30 as
carrier.
3.6. Fourier transform infrared spectroscopy
In order to characterise interactions between the drugs and car-
riers, infrared spectra were recorded.The FTIR spectrum of pure
tanshinone IIA, CT, total tanshinones, polymer alone, SDs and
physical mixtures were investigated (Fig. 9). The FTIR spectra
of SDs and the corresponding physical mixture were the su-
perposition of spectra of the individual components. Analysis
of the spectra for both SDs as well as the physical mixtures
did not demonstrate any changes for the specific absorption
bands for the polymers or the drugs, suggesting that there were
no chemical interactions between tanshinone IIA, CT, total
tanshinones and carriers. Similar results have reported SDs of
tanshinone IIA using poloxamer 188 as a carrier [28].
3.7. PXRD diffractograms
The PXRD diffractograms of total tanshinones, PEG 6000,
poloxamer 188, PVP K30, the solid dispersions and physical mix-
tures were shown in Fig. 10. The X-ray diffractogram of total
tanshinones has sharp peaks between diffraction angles (2θ)
6.85°–31.26° (Fig. 10A). In diffractograms of total tanshinones-
PEG 6000, total tanshinones-poloxamer 188 SDs and physical
mixtures, the major crystal peaks are characteristic crystal-
line peaks of PEG 6000 (Fig. 10B–D) and poloxamer 188
(Fig. 10E–G). The peaks between diffraction angles (2θ) 6.85°–
9.31°of total tanshinones still remained in the SD and physical
mixture systems, but the relative intensity is lower.The peaks
between 24.91° and 29.12° of total tanshinones may overlap
with the carriers. No visible differences in PXRD diffractograms
were found between the two SDs and physical mixtures. Al-
though in DSC thermographs, no endothermic response was
recorded for total tanshinones and single ingredients due to
Fig. 7 – Scanning electron microphotographs of solid dispersions and physical mixtures with PVP K30 as carrier (1:6 w/w).
(A) Tanshinone IIA-PVP K30 solid dispersion, (B) tanshinone IIA-PVP K30 physical mixture, (C) cryptotanshinone-PVP K30
solid dispersion, (D) cryptotanshinone-PVP K30 physical mixture, (E) total tanshinones-PVP K30 solid dispersion, (F) total
tanshinones-PVP K30 physical mixture.
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the possible solubility of drug substances in molten carriers,
the total tanshinones may exist in microcrystalline form in PEG
6000 and poloxamer 188 SDs with the formation of eutectic
mixture during SD preparation. In the total tanshinones-PVP
K30 SD (Fig. 10H–J), compared to the diffractograms of total
tanshinones-PVP K30 SD with physical mixture, the crystal
peaks of total tanshinones in the SD is obviously lower, some
even disappeared.This may suggest that the crystal growth of
total tanshinones may be prohibited by PVP K30 in SDs to some
extent, and at this weight ratio of drug and PVP K30, total
tanshinones were still in the form of microcrystal in total
tanshinones-PVP K30 SD system.
4. Conclusion
Solid dispersions of tanshinone IIA, CT and total tanshinones
were successfully prepared using PEG6000, poloxamer 188, and
Fig. 8 – DSC thermograms of raw materials, solid dispersions and physical mixtures (1:6 w/w). From the bottom: PVP K30-
total tanshinones physical mixture (PVP-total mix), PVP K30-total tanshinones solid dispersion (PVP-total SD), poloxamer
188-total tanshinones physical mixture (poloxamer-total mix), poloxamer 188-total tanshinones solid dispersion
(poloxamer-total SD), PEG 6000-total tanshinones mixture (PEG-total mix), PEG 6000-total tanshinones solid dispersion
(PEG-total SD), total tanshinones, PVP K30-cryptotanshinone physical mixture (PVP-CT mix), PVP K30-cryptotanshinone
solid dispersion (PVP-CT SD), poloxamer 188-cryptotanshinone physical mixture (poloxamer-CT mix), poloxamer 188-
cryptotanshinone solid dispersion (poloxamer-CT SD), PEG 6000-cryptotanshinone mixture (PEG-CT mix), PEG 6000-
cryptotanshinone solid dispersions (PEG-CT SD), pure cryptotanshinone (cryptotanshinone, PVP K30-tanshinone IIA
physical mixture (PVP-IIA mix), PVP K30-tanshinone IIA solid dispersion (PVP-IIA SD), poloxamer 188-tanshinone IIA
physical mixture (poloxamer-IIA mix), poloxamer 188-tanshinone IIA solid dispersion (poloxamer-IIA SD), PEG 6000-
tanshinone IIA mixture (PEG-IIA mix), PEG 6000-tanshinone IIA solid dispersion (PEG-IIA SD), pure tanshinone IIA
(Tanshinone IIA), PVP K30, poloxamer 188 and PEG 6000.
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PVP k30 as hydrophilic carriers.The solubility, dissolution rate
of tanshinone IIA and CT were dramatically elevated com-
pared with their physical mixtures and pure compounds.
Among these three commonly used hydrophilic carriers,
poloxamer 188 proved to be the best carrier for tanshinone IIA,
CT and total tanshinones for SD preparation with higher dis-
solution rate and feasible manufacture method.The SDs were
characterised by SEM, DSC, FTIR and PXRD and the results con-
firmed that tanshinone IIA, CT and total tanshinones existed
in the form of microcrystal or superfine crystal in SDs pre-
pared with hydrophilic carriers of PEG 6000, poloxamer 188 and
PVP K30 at the weight ratio of 1:6. No interactions of drug sub-
stances and the carriers were found in all SDs prepared.These
results suggest that SD using poloxamer 188 is a feasible and
highly effective technique to improve the solubility and dis-
solution rate of tanshinones. As a drug candidate for various
conditions such as cancer and cardiovascular diseases, further
studies of tanshinones and applications of relevant SD tech-
niques may help to improve the clinical efficacy and safety of
tanshinone formulations.
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Fig. 9 – FTIR spectrogram of raw materials, solid dispersions and physical mixtures (1:6 w/w).
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